GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial

被引：0

作者：

Shen, Lin ^{[1
]}

Gong, Jifang ^{[1
]}

Song, Yuqin ^{[2
]}

Ye, Dingwei ^{[3
]}

Lu, Zhihao ^{[1
]}

Wang, Siyang ^{[4
]}

Peng, Peijian ^{[4
]}

Chen, Jianhua ^{[5
]}

Jiang, Ou ^{[6
]}

Zhang, Guojun ^{[7
]}

Bai, Yuxian ^{[8
]}

Pan, Jianji ^{[9
]}

Ma, Chunguang ^{[3
]}

Chen, Li ^{[10
]}

Ba, Yi ^{[11
]}

Li, Qi ^{[12
]}

Lu, Ping ^{[13
]}

Zhang, Lingli ^{[14
]}

Yin, Xianli ^{[15
]}

Gu, Shanzhi ^{[15
]}

Zhang, Huilai ^{[16
]}

Su, Hang ^{[17
]}

Jiang, Yongsheng ^{[18
,19
]}

Cao, Bangwei ^{[20
]}

Han, Weiqing ^{[15
]}

Sun, Yan ^{[21
]}

Zhang, Feng ^{[22
]}

Ouyang, Weiwei ^{[23
]}

Dong, Haiying ^{[24
]}

Guo, Jianming ^{[25
]}

Guo, Yabing ^{[26
]}

Xu, Chongyuan ^{[26
]}

Qi, Junyuan ^{[27
]}

Wang, Li ^{[28
]}

Lv, Jun ^{[29
]}

Wang, Xiang ^{[12
]}

Chen, Chris ^{[30
]}

Li, Jing ^{[30
]}

Zheng, Yong ^{[30
]}

Jin, Ge ^{[31
]}

Yang, Yining ^{[31
]}

Zhao, Guodong ^{[31
]}

Yang, Fan ^{[32
]}

Xu, Kehui ^{[32
]}

Liang, Xiangying ^{[32
]}

Pan, Zhaoyang ^{[32
]}

Meng, Haijin ^{[32
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[3] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Urol, Shanghai, Peoples R China

[4] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China

[5] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Thorac Med Dept 1, Changsha, Peoples R China

[6] Second Gen Hosp Neijiang City, Neijiang, Peoples R China

[7] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[8] Harbin Med Univ, Canc Hosp, Haerbin, Peoples R China

[9] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[10] Nanchang Univ, Affiliated Hosp 5, Nanchang, Jiangxi, Peoples R China

[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[12] Shanghai Gen Hosp, Shanghai, Peoples R China

[13] Xinxiang Med Sch, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China

[14] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[15] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[16] Tianjin Med Univ Canc Inst & Hosp, Lymphoma Dept, Tianjin, Peoples R China

[17] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[18] Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan, Peoples R China

[19] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Peoples R China

[20] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[21] Peking Univ Canc Hosp & Inst, Dept Oncol Radiotherapy, Beijing, Peoples R China

[22] Bengbu Med Sch, Affiliated Hosp 1, Bengbu, Peoples R China

[23] Guizhou Canc Hosp, Guiyang, Peoples R China

[24] Zhengjiang Prov Peoples Hosp, Hangzhou Med Coll, Peoples Hosp, Hangzhou, Peoples R China

[25] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[26] Nanfang Hosp, Southern Med Sch, Affiliated Hosp 1, Guangzhou, Peoples R China

[27] Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[28] Jiangsu Prov Hosp, Nanjing, Peoples R China

[29] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[30] WuXi Biol Shanghai Co Ltd, Shanghai, Peoples R China

[31] GloriousMed Technol Co Ltd, Beijing, Peoples R China

[32] Guangzhou Gloria Biosci Co Ltd, Beijing, Peoples R China

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-3275

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3275

引用

页数：4

共 50 条

[21] A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.
Shen, Lin
Cao, Junning
Li, Jin
Pan, Hongming
Xu, Nong
Zhang, Yan
Wang, Jingru
Wang, Yin
Dai, Hangjun
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[22] The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).
Zandberg, Dan Paul
Velez, Maria A.
Menk, Ashley, V
Liu, Angen
Skinner, Heath Devin
Duvvuri, Umamaheswar
Ohr, James
Chiosea, Simion, I
Nilsen, Marci Lee
Clump, David Anthony
Ferris, Robert L.
Delgoffe, Greg
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] Tumor microenvironment evaluation to predict anti-PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.
Liao, Wangjun
Shi, Min
Zeng, Dongqiang
Luo, Huiyan
Xiao, Jian
Ye, Feng
Xiong, Hailin
Yuan, Xia
Huang, Yisheng
Li, Yongqiang
Huang, Na
Wu, Jianhua
Li, Shaowei
Zheng, Siting
Wu, Jiani
Sun, Li
Rong, Xiaoxiang
Wang, Chunlin
Guo, Jian
Deng, Qiong
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 415 - 415
[24] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies
Song, Xuyang
Khan, Anis A.
Zhou, Diansong
Elgeioushi, Nairouz
Walcott, Farzana
Ren, Song
Gibbs, Megan
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 373 - 382
[25] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
Zhou, Cai
He, Yayi
Ren, Shengxiang
Li, Wei
Zhu, Jun
Yu, Jia
Wang, Lei
Xiong, Anwen
Xu, Nong
Mao, Chenyu
Pan, Beiqing
Liu, Ying
Zhou, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies
Xuyang Song
Anis A. Khan
Diansong Zhou
Nairouz Elgeioushi
Farzana Walcott
Song Ren
Megan Gibbs
Cancer Chemotherapy and Pharmacology, 2022, 89 : 373 - 382
[27] Phase 1 clinical trial of ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) for patients with advanced cancer
Figlin, R
Belldegrun, A
Crawford, J
Lohner, M
Roskos, L
Yang, XD
Foon, KA
Schwab, G
Weiner, L
INTERNATIONAL JOURNAL OF CANCER, 2002, : 87 - 87
[28] A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Ott, Patrick A.
Hu-Lieskovan, Siwen
Chmielowski, Bartosz
Govindan, Ramaswamy
Naing, Aung
Bhardwaj, Nina
Margolin, Kim
Awad, Mark M.
Hellmann, Matthew D.
Lin, Jessica J.
Friedlander, Terence
Bushway, Meghan E.
Balogh, Kristen N.
Sciuto, Tracey E.
Kohler, Victoria
Turnbull, Samantha J.
Besada, Rana
Curran, Riley R.
Trapp, Benjamin
Scherer, Julian
Poran, Asaf
Harjanto, Dewi
Barthelme, Dominik
Ting, Ying Sonia
Dong, Jesse Z.
Ware, Yvonne
Huang, Yuting
Huang, Zhengping
Wanamaker, Amy
Cleary, Lisa D.
Moles, Melissa A.
Manson, Kelledy
Greshock, Joel
Khondker, Zakaria S.
Fritsch, Ed
Rooney, Michael S.
DeMario, Mark
Gaynor, Richard B.
Srinivasan, Lakshmi
CELL, 2020, 183 (02) : 347 - +
[29] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
Ganju, Vinod
Cooper, Adam
Gao, Bo
Wilkinson, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
Ho, Ching-Liang
Chao, Tsu-Yi
Chang, Chia Lun
Lin, Hsuan-Yu
Yang, Futang
Wang, Qingyu
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →